Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE in Steroid Refractory Acute GVHD
NCT00408928Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2005
- Primary completion
- Sep 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Response to Bortezomib. Started Nov 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00408928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408928.